-
1
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-2.
-
(2000)
Nature
, vol.406
, Issue.6797
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
Van De Rijn, M.4
Jeffrey, S.S.5
Rees, C.A.6
-
2
-
-
4143150688
-
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
-
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.16
, pp. 5367-5374
-
-
Nielsen, T.O.1
Hsu, F.D.2
Jensen, K.3
Cheang, M.4
Karaca, G.5
Hu, Z.6
-
3
-
-
40949121882
-
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
-
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(5):1368-76.
-
(2008)
Clin Cancer Res off J Am Assoc Cancer Res
, vol.14
, Issue.5
, pp. 1368-1376
-
-
Cheang, M.C.1
Voduc, D.2
Bajdik, C.3
Leung, S.4
McKinney, S.5
Chia, S.K.6
-
4
-
-
33745660509
-
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
-
Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22-34.
-
(2006)
Histopathology
, vol.49
, Issue.1
, pp. 22-34
-
-
Fulford, L.G.1
Easton, D.F.2
Reis-Filho, J.S.3
Sofronis, A.4
Gillett, C.E.5
Lakhani, S.R.6
-
5
-
-
34248218713
-
Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival
-
Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res BCR. 2007;9(1):R4.
-
(2007)
Breast Cancer Res BCR
, vol.9
, Issue.1
-
-
Fulford, L.G.1
Reis-Filho, J.S.2
Ryder, K.3
Jones, C.4
Gillett, C.E.5
Hanby, A.6
-
6
-
-
20344377896
-
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer
-
Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(11):4003-11.
-
(2005)
Clin Cancer Res off J Am Assoc Cancer Res
, vol.11
, Issue.11
, pp. 4003-4011
-
-
Arnes, J.B.1
Brunet, J.S.2
Stefansson, I.3
Begin, L.R.4
Wong, N.5
Chappuis, P.O.6
-
7
-
-
60249089283
-
Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically
-
Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 2009;33(2):163-75.
-
(2009)
Am J Surg Pathol
, vol.33
, Issue.2
, pp. 163-175
-
-
Subhawong, A.P.1
Subhawong, T.2
Nassar, H.3
Kouprina, N.4
Begum, S.5
Vang, R.6
-
8
-
-
33745190482
-
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis
-
Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Modern Pathol Off J United States Can Acad Pathol Inc. 2006;19(7):999-1009.
-
(2006)
Modern Pathol off J United States Can Acad Pathol Inc
, vol.19
, Issue.7
, pp. 999-1009
-
-
Reis-Filho, J.S.1
Savage, K.2
Lambros, M.B.3
James, M.4
Steele, D.5
Jones, R.L.6
-
9
-
-
79959360288
-
Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)
-
author reply 1-2
-
Rakha EA, Ellis IO, Reis-Filho JS. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Modern Pathol Off J United States Can Academy Pathol Inc. 2008;21(8):1060-1. author reply 1-2.
-
(2008)
Modern Pathol off J United States Can Academy Pathol Inc
, vol.21
, Issue.8
, pp. 1060-1061
-
-
Rakha, E.A.1
Ellis, I.O.2
Reis-Filho, J.S.3
-
10
-
-
43949095489
-
How basal are triple-negative breast cancers?
-
Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123(1):236-40.
-
(2008)
Int J Cancer
, vol.123
, Issue.1
, pp. 236-240
-
-
Bertucci, F.1
Finetti, P.2
Cervera, N.3
Esterni, B.4
Hermitte, F.5
Viens, P.6
-
11
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(8):1160-7.
-
(2009)
J Clin Oncol off J Am Soc Clin Oncol
, vol.27
, Issue.8
, pp. 1160-1167
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.3
Leung, S.4
Voduc, D.5
Vickery, T.6
-
12
-
-
72449204608
-
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
-
de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010;119(1):119-26.
-
(2010)
Breast Cancer Res Treat
, vol.119
, Issue.1
, pp. 119-126
-
-
De Ronde, J.J.1
Hannemann, J.2
Halfwerk, H.3
Mulder, L.4
Straver, M.E.5
Vrancken Peeters, M.J.6
-
13
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Epub 2012/09/25
-
Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. Epub 2012/09/25.
-
(2012)
Nature
, vol.490
, Issue.7418
, pp. 61-70
-
-
-
14
-
-
59449094654
-
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
-
Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15(2):441-51.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.2
, pp. 441-451
-
-
Andre, F.1
Job, B.2
Dessen, P.3
Tordai, A.4
Michiels, S.5
Liedtke, C.6
-
15
-
-
67651148274
-
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling
-
Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009;16(2):115-25.
-
(2009)
Cancer Cell
, vol.16
, Issue.2
, pp. 115-125
-
-
Gewinner, C.1
Wang, Z.C.2
Richardson, A.3
Teruya-Feldstein, J.4
Etemadmoghadam, D.5
Bowtell, D.6
-
16
-
-
20144387695
-
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
-
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65(7):2554-9.
-
(2005)
Cancer Res
, vol.65
, Issue.7
, pp. 2554-2559
-
-
Saal, L.H.1
Holm, K.2
Maurer, M.3
Memeo, L.4
Su, T.5
Wang, X.6
-
17
-
-
84862526929
-
The clonal andmutational evolution spectrum of primary triple-negative breast cancers
-
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal andmutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-9.
-
(2012)
Nature
, vol.486
, Issue.7403
, pp. 395-399
-
-
Shah, S.P.1
Roth, A.2
Goya, R.3
Oloumi, A.4
Ha, G.5
Zhao, Y.6
-
18
-
-
79960015997
-
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
-
This article describes the identification of six TNBC subtypes with unique gene expression: two basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype. Gene expression analysis enabled identification of TNBC cell line models representative of these subtypes, against which different targeted therapy was tested. This provided proof of concept that analysis of distinct gene-expression profiles can be used as the basis of therapy selection, which may be useful for assigning TNBC patients to more appropriate targeted therapy
-
18.• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. This article describes the identification of six TNBC subtypes with unique gene expression: two basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype. Gene expression analysis enabled identification of TNBC cell line models representative of these subtypes, against which different targeted therapy was tested. This provided proof of concept that analysis of distinct gene-expression profiles can be used as the basis of therapy selection, which may be useful for assigning TNBC patients to more appropriate targeted therapy.
-
(2011)
J Clin Invest
, vol.121
, Issue.7
, pp. 2750-2767
-
-
Lehmann, B.D.1
Bauer, J.A.2
Chen, X.3
Sanders, M.E.4
Chakravarthy, A.B.5
Shyr, Y.6
-
19
-
-
84884567614
-
Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer
-
Abstract 1005. Presented at - 2013 ASCO Annual Meeting
-
Masuda H, Baggerl KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(15 suppl):Abstract 1005. Presented at - 2013 ASCO Annual Meeting.
-
(2013)
J Clin Oncol off J Am Soc Clin Oncol
, vol.31
, Issue.15 SUPPL.
-
-
Masuda, H.1
Baggerl, K.A.2
Wang, Y.3
Zhang, Y.4
Gonzalez-Angulo, A.M.5
Meric-Bernstam, F.6
-
20
-
-
18844410329
-
BRCA1 promoter methylation in sporadic breast tumors: Relationship to gene expression profiles
-
Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91(2):179-86.
-
(2005)
Breast Cancer Res Treat
, vol.91
, Issue.2
, pp. 179-186
-
-
Matros, E.1
Wang, Z.C.2
Lodeiro, G.3
Miron, A.4
Iglehart, J.D.5
Richardson, A.L.6
-
21
-
-
4944229642
-
Hallmarks of 'BRCAness' in sporadic cancers
-
Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-9.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.10
, pp. 814-819
-
-
Turner, N.1
Tutt, A.2
Ashworth, A.3
-
22
-
-
77949908546
-
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
-
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-53.
-
(2010)
J Clin Oncol
, vol.28
, Issue.7
, pp. 1145-1153
-
-
Silver, D.P.1
Richardson, A.L.2
Eklund, A.C.3
Wang, Z.C.4
Szallasi, Z.5
Li, Q.6
-
23
-
-
39749119151
-
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers
-
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108(2):289-96.
-
(2008)
Breast Cancer Res Treat
, vol.108
, Issue.2
, pp. 289-296
-
-
Byrski, T.1
Gronwald, J.2
Huzarski, T.3
Grzybowska, E.4
Budryk, M.5
Stawicka, M.6
-
24
-
-
84884546598
-
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
-
abst 1004
-
Von Minckwitz G, Schneeweiss A, Salat C. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 2013;31(suppl):abst 1004.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Von Minckwitz, G.1
Schneeweiss, A.2
Salat, C.3
-
25
-
-
84896723087
-
Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
-
Oral Session
-
Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). San Antonio Breast Cancer Symposium 2013. 2013; Oral Session 5:01.
-
(2013)
San Antonio Breast Cancer Symposium 2013
, vol.5
, pp. 01
-
-
Sikov, W.1
Berry, D.2
Perou, C.3
Singh, B.4
Cirrincione, C.5
Tolaney, S.6
-
26
-
-
84904188903
-
Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis
-
Epub 2014/02/18
-
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014. Epub 2014/02/18.
-
(2014)
Lancet
-
-
Cortazar, P.1
Zhang, L.2
Untch, M.3
Mehta, K.4
Costantino, J.P.5
Wolmark, N.6
-
27
-
-
21644482340
-
Targeting the DNA repair defect of BRCA tumours
-
Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5(4):388-93.
-
(2005)
Curr Opin Pharmacol
, vol.5
, Issue.4
, pp. 388-393
-
-
Turner, N.1
Tutt, A.2
Ashworth, A.3
-
28
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
-
(2005)
Nature
, vol.434
, Issue.7035
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
Tutt, A.N.4
Johnson, D.A.5
Richardson, T.B.6
-
29
-
-
78751610848
-
Iniparib plus chemotherapy in metastatic triple-negative breast cancer
-
O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-14.
-
(2011)
N Engl J Med
, vol.364
, Issue.3
, pp. 205-214
-
-
O'Shaughnessy, J.1
Osborne, C.2
Pippen, J.E.3
Yoffe, M.4
Patt, D.5
Rocha, C.6
-
30
-
-
80052330662
-
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)
-
abstract #1007
-
O'Shaughnessy J SL, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29:abstract #1007.
-
(2011)
J Clin Oncol
, vol.29
-
-
O'Shaughnessy, J.S.L.1
Danso, M.A.2
-
31
-
-
84890257506
-
PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer
-
abstr 1003
-
Telli M, Jensen K, Kurian A. PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. J Clin Oncol 2013;31(suppl):abstr 1003.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Telli, M.1
Jensen, K.2
Kurian, A.3
-
32
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
-
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44.
-
(2010)
Lancet
, vol.376
, Issue.9737
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
Domchek, S.M.4
Audeh, M.W.5
Weitzel, J.N.6
-
33
-
-
80052389761
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study
-
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-61.
-
(2011)
Lancet Oncol
, vol.12
, Issue.9
, pp. 852-861
-
-
Gelmon, K.A.1
Tischkowitz, M.2
Mackay, H.3
Swenerton, K.4
Robidoux, A.5
Tonkin, K.6
-
34
-
-
84906937713
-
Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
-
Session Abstract 02
-
Rugo HS, Olopade O, DeMichele A, van't Veer L, Buxton M, Hylton N, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. San Antonio Breast Cancer Symposium. 2013;Session 5:Abstract 02.
-
(2013)
San Antonio Breast Cancer Symposium
, vol.5
-
-
Rugo, H.S.1
Olopade, O.2
DeMichele, A.3
Van't Veer, L.4
Buxton, M.5
Hylton, N.6
-
35
-
-
84862526929
-
The clonal andmutational evolution spectrum of primary triple-negative breast cancers
-
Epub 2012/04/13
-
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal andmutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012. Epub 2012/04/13
-
(2012)
Nature
-
-
Shah, S.P.1
Roth, A.2
Goya, R.3
Oloumi, A.4
Ha, G.5
Zhao, Y.6
-
36
-
-
84866681744
-
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
-
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036-47.
-
(2012)
Cancer Discov
, vol.2
, Issue.11
, pp. 1036-1047
-
-
Ibrahim, Y.H.1
Garcia-Garcia, C.2
Serra, V.3
He, L.4
Torres-Lockhart, K.5
Prat, A.6
|